• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BTG

Delcath Systems raises another $9.5m

August 20, 2019 By Nancy Crotti

delcath-systems

Delcath Systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Oncology, Uncategorized, Wall Street Beat Tagged With: BTG, Delcath Systems Inc.

BTG touts use of radiopaque drug-eluting bead

January 28, 2019 By Sarah Faulkner

BTG's Interventional Oncology Logo

BTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead. The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG. The beads’ radiopacity enable […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: BTG

Boston Scientific puts $4B on the table for BTG’s interventional portfolio

November 20, 2018 By Sarah Faulkner

Boston Scientific BTG

Boston Scientific (NYSE:BSX) said today that it agreed to offer $4.24 billion to acquire British medical device maker BTG (LON:BTG) and its portfolio of interventional drug-device therapies. The Marlborough, Mass.-based company said that its acquisition of BTG will augment Boston Scientific’s capabilities in the treatment of cancer and pulmonary embolism. “We are confident that the addition of these therapies […]

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific, BTG

Medtech stories we missed this week: June 22, 2018

June 22, 2018 By Danielle Kirsh

missed-medtech-0622

From Accuray’s India approval to Masimo and PositiveID launching a Bluetooth-enabled thermometer, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. India approves Accuray’s Radixact X9 radiation therapy device Accuray announced in a June 21 press release that it has received an Atomic Energy Regulatory Board Type Approval in […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Imaging, Regulatory/Compliance, Surgical Tagged With: Accuray Inc., Arcuro Medical, BTG, Masimo, medtech, NuSight, PositiveID, Tenon Medical, TransMed7

BTG touts one-year follow-up data for Ekos pulmonary embolism therapy

February 6, 2018 By Sarah Faulkner

Ekos

BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial. Researchers studied the 12-month outcomes of 101 patients who were treated over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. Pulmonary embolism patients treated with BTG’s Ekos […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: BTG

Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads

October 10, 2017 By Sarah Faulkner

BTG

Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer. The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Imaging, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: BTG

BTG helps fund immuno-oncology drug-device research programs

August 21, 2017 By Sarah Faulkner

BTG

BTG (LON:BTG) and the Society of Interventional Oncology said today that it expanded its immuno-oncology/interventional oncology research grant program. The group launched a second round of funding, designed help evaluate minimally invasive, image-guided therapies that use the body’s own immune system to treat cancer. The program is specifically looking to fund proposals that assess how interventional […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Imaging, Immunotherapy, Oncology, Pharmaceuticals, Research & Development Tagged With: BTG, societyofinterventionaloncology

Study: Ekos ultrasound device provides relief to patients with chronic deep vein thrombosis

June 19, 2017 By Sarah Faulkner

Ekos

BTG (LON:BTG) touted data last week showing that patients with chronic deep vein thrombosis and post-thrombotic syndrome can be safely and effectively treated with the Ekos device and anti-coagulation drugs. The study’s protocol is the 1st treatment regimen proven to reduce the symptoms of PTS and demonstrate an improvement in quality of life for patients […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: BTG

BTG touts digital patient engagement platform with TheraSphere treatment

June 12, 2017 By Sarah Faulkner

BTG

BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy. The study found that patients experienced sustained quality of life up to 3 months after treatment. The company touted the study of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Patient Monitoring, Vascular, Wall Street Beat Tagged With: BTG

Ultrasound-drug combo treats pulmonary embolism in less time with fewer drugs

May 25, 2017 By Sarah Faulkner

Ekos

When venous clots break off and travel through a patient’s circulatory system, they can become trapped in the lung and block blood flow. This strains the heart’s ability to pump blood through the lungs and can ultimately lead to heart failure. Traditionally, patients with pulmonary embolisms are treated overnight with systemic infusions of tissue plasminogen […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: BTG

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS